Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MYNZ Mainz Biomed B.V.

Trading 03-03 13:13:51 EST

0.7543

-0.0124

-1.62%

High0.7600	Low0.6800	Vol95.57K
Open0.7382	D1 Closing0.7667	Amplitude10.43%
Mkt Cap6.83M	Tradable Cap6.26M	Total Shares9.06M
T/O69.55K	T/O Rate1.15%	Tradable Shares8.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MYNZ","market":"US","secType":"STK","nameCN":"Mainz Biomed B.V.","latestPrice":0.7543,"timestamp":1772561203242,"preClose":0.7667,"halted":0,"volume":95571,"delay":0,"changeRate":-0.016173209860440952,"floatShares":8300635,"shares":9060142,"eps":-8.39035,"marketStatus":"Trading","change":-0.0124,"latestTime":"03-03 13:13:51 EST","open":0.7382,"high":0.76,"low":0.68,"amount":69554.6337087,"amplitude":0.104343,"askPrice":0.77,"askSize":35,"bidPrice":0.7416,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-8.39035,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772571600000},"marketStatusCode":2,"adr":0,"listingDate":1635998400000,"exchange":"NASDAQ","adjPreClose":0.7667,"preHourTrading":{"tag":"盘前","latestPrice":0.724,"preClose":0.7667,"latestTime":"09:28 EST","volume":1200,"amount":889.84176,"timestamp":1772548093313,"change":-0.0427,"changeRate":-0.055693,"amplitude":0.035607},"postHourTrading":{"tag":"盘后","latestPrice":0.7502,"preClose":0.7667,"latestTime":"19:08 EST","volume":176,"amount":133.3852,"timestamp":1772496524069,"change":-0.0165,"changeRate":-0.021521,"amplitude":0.021521},"volumeRatio":0.809097},"requestUrl":"/m/hq/s/MYNZ/tweets","defaultTab":"tweets","newsList":[{"id":"2616321485","title":"Mainz Biomed NV Files Initial Beneficial Ownership Statement for Director David E. Lazar","url":"https://stock-news.laohu8.com/highlight/detail?id=2616321485","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616321485?lang=en_us&edition=fundamental","pubTime":"2026-03-03 23:11","pubTimestamp":1772550680,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV filed an initial statement of beneficial ownership naming David E. Lazar, who is listed as a Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL88fDn8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2613171989","title":"Mainz Biomed to Present Blood-Based mRNA Biomarker Data at Digestive Disease Week 2026 Pancreatic Cancer Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2613171989","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613171989?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:31","pubTimestamp":1771936295,"startTime":"0","endTime":"0","summary":"Mainz Biomed to Present Blood-Based mRNA Biomarker Data at Digestive Disease Week 2026 Pancreatic Cancer Session               Mainz Biomed N.V. will attend Digestive Disease Week (DDW) 2026 in Chicag","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL64Rrxh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","BK4139","BK4588","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2612362652","title":"Mainz Biomed NV Files Initial Beneficial Ownership Statement for Director Hans Hekland","url":"https://stock-news.laohu8.com/highlight/detail?id=2612362652","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612362652?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:09","pubTimestamp":1771538988,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV filed an initial statement of beneficial ownership  reporting that Hans Hekland, a director, is a beneficial owner of the company’s securities. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL3n14WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mainz Biomed NV Files Initial Beneficial Ownership Statement for Director Hans Hekland","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2612454980","title":"Mainz Biomed Secures $6 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2612454980","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612454980?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:32","pubTimestamp":1771331568,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV announced a $6 million private placement through the sale of Convertible Non-Redeemable Preferred Stock to investor David Lazar. The financing will occur in two tranches of $3 million each, with the first closing completed and the second expected before April 15, 2026, pending stockholder approval. Proceeds will fund operations, address liabilities, and support the company's shift to focus on its U.S. pancreatic cancer detection program. David Lazar has been appointed Chairman of the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL7SP2pV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2612454906","title":"Press Release: Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2612454906","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612454906?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:30","pubTimestamp":1771331400,"startTime":"0","endTime":"0","summary":"BERKELEY, Calif. and MAINZ, Germany, Feb. 17, 2026  -- Mainz Biomed N.V. , a molecular genetics diagnostic company specializing in the early detection of cancer, announced a series of strategic transactions designed to strengthen its liquidity position, transition the business to a focus on its pancreatic cancer detection program in the U.S., and provide flexibility as the Company continues its operations while evaluating growth opportunities and broader strategic alternatives.On February 13, 2026, Mainz Biomed N.V.  entered into a securities purchase agreement for a 6.0 USD million private placement with investor David Lazar. The financing will be completed in two tranches of 3.0 USD million each through the issuance of Convertible Non-Redeemable Preferred Stock. The first 3.0 USD million closing was completed on February 13, 2026. The second 3.0 USD million closing is expected to occur following receipt of required stockholder approvals and prior to April 15, 2026. Net proceeds from ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USD","BK4022","R","MYNZ","BK4232","PCR","BK4139"],"gpt_icon":0},{"id":"2610672569","title":"Mainz Biomed completes ATM share sales, retains capacity","url":"https://stock-news.laohu8.com/highlight/detail?id=2610672569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610672569?lang=en_us&edition=fundamental","pubTime":"2026-02-11 06:33","pubTimestamp":1770762828,"startTime":"0","endTime":"0","summary":"An announcement from Mainz Biomed B.V. ( ($MYNZ) ) is now available. Mainz Biomed N.V. entered into an equity distribution agreement on October 1, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mainz-biomed-completes-atm-share-sales-retains-capacity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mainz-biomed-completes-atm-share-sales-retains-capacity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MYNZ"],"gpt_icon":0},{"id":"2606022688","title":"Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CEO and Director Guido Baechler","url":"https://stock-news.laohu8.com/highlight/detail?id=2606022688","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606022688?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:03","pubTimestamp":1769461402,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has filed an initial statement of beneficial ownership. The filing names Guido Baechler as the beneficial owner, who serves as Chief Executive Officer and Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL788kwB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CEO and Director Guido Baechler","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2604948604","title":"Massive Insider Move: Major Investor Makes Colossal Bet on Mainz Biomed","url":"https://stock-news.laohu8.com/highlight/detail?id=2604948604","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604948604?lang=en_us&edition=fundamental","pubTime":"2026-01-17 10:03","pubTimestamp":1768615402,"startTime":"0","endTime":"0","summary":"New insider activity at Mainz Biomed B.V. ( ($MYNZ) ) has taken place on January 16, 2026. Significant shareholder Kevin Michael Donahue has dramat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/massive-insider-move-major-investor-makes-colossal-bet-on-mainz-biomed-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/massive-insider-move-major-investor-makes-colossal-bet-on-mainz-biomed-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2604916193","title":"Mainz Biomed NV Files Initial Beneficial Ownership Statement; Kevin Donahue Listed as 10% Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2604916193","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604916193?lang=en_us&edition=fundamental","pubTime":"2026-01-17 04:38","pubTimestamp":1768595885,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Kevin Michael Donahue as a 10% owner of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLKWjlX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Mainz Biomed NV Files Initial Beneficial Ownership Statement; Kevin Donahue Listed as 10% Owner","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2603162076","title":"Mainz Biomed Unveils Pancreatic Cancer mRNA Blood Test Study Results at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603162076","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603162076?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:17","pubTimestamp":1768396644,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a molecular genetic diagnostics company specializing in early cancer detection, has announced that it will present results from a verification study focused on pancreatic cancer at the upcoming 2026 Annual Meeting of the American Association for Cancer Research , scheduled to take place from April 17 to 22 in San Diego, California. The study involves a proprietary, blood-based mRNA biomarker signature combined with an AI-based modeling approach for the detection of ductal adenocarcinoma of the pancreas and differentiation from intraductal papillary mucinous neoplasms. The results are set to be presented at the AACR conference.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDLBjSDc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2601389887","title":"Mainz Biomed Provides Review of 2025 Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389887","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389887?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:15","pubTimestamp":1767622500,"startTime":"0","endTime":"0","summary":"Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3212863/0/en/Mainz-Biomed-Provides-Review-of-2025-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456854461.SGD","CRC","BK4213","BK4139","PCR","MYNZ","LU0266512127.USD"],"gpt_icon":0},{"id":"2601881457","title":"Mainz Biomed Secures State Funding for Pancreatic Cancer Detection Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881457","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881457?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:17","pubTimestamp":1767619045,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has announced that its pancreatic cancer early detection project has received government funding from the Investitions- und Strukturbank Rheinland-Pfalz . Under the ISB’s Innovation and Technology Funding Program, the state of Rhineland-Palatinate will cover up to 50% of the total project costs. This public funding highlights the scientific and societal significance of Mainz Biomed’s non-invasive blood test for the early detection of pancreatic cancer and is set to accelerate its development. No other beneficiary organizations were mentioned.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL5PSpqD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2588053403","title":"Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053403","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053403?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680526,"startTime":"0","endTime":"0","summary":"Mainz Biomed N.V., a molecular genetics diagnostic company specializing in early cancer detection, has announced a partnership with DoctorBox, one of Germany's leading digital health platforms. Through this collaboration, Mainz Biomed's DNA-based colorectal cancer screening test, ColoAlert, will be added to DoctorBox's portfolio of preventive healthcare services. The partnership aims to expand access to at-home colorectal cancer screening, with laboratory analysis provided by the European Oncology Lab. This move supports Mainz Biomed's European growth strategy and highlights the increasing role of digital solutions in preventive medicine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLb27KLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","LU0314104364.USD","MYNZ","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2584937226","title":"Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937226","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937226?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:03","pubTimestamp":1763470996,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV announced the signing of a Memorandum of Understanding  with OncoVanguard8 to introduce its DNA-based colorectal cancer screening test, ColoAlert, to South America, beginning with Peru. The agreement outlines commercial, legal, and regulatory terms, as well as the go-to-market strategy for the initial territory. The companies aim to finalize a distribution agreement in the coming weeks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL83B0n0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","LU2095319765.USD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","MYNZ","NDAQ","BK4585"],"gpt_icon":0},{"id":"2582797233","title":"Mainz Biomed NV Showcases Cancer Detection Solutions at MEDICA","url":"https://stock-news.laohu8.com/highlight/detail?id=2582797233","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582797233?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:02","pubTimestamp":1762952527,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV will participate in MEDICA 2025, one of the world's leading healthcare trade shows, taking place from November 17 to 20, 2025, in Düsseldorf, Germany. The company will showcase its flagship product, ColoAlert, a molecular stool-based screening test for early detection of colorectal cancer, along with other upcoming diagnostic solutions for early-stage cancer diagnosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5qdMTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4588","BK4585","BK4139","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","MYNZ","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2582879240","title":"Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879240?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:04","pubTimestamp":1762779865,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1c2qcn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","BK4585","LU0314104364.USD","NDAQ","IE00BKPKM429.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2575778778","title":"Mainz Biomed NV to Attend Maxim Growth Summit in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2575778778","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575778778?lang=en_us&edition=fundamental","pubTime":"2025-10-15 21:01","pubTimestamp":1760533287,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a molecular genetics diagnostic company specializing in early cancer detection, will attend the 2025 Maxim Growth Summit on October 22-23, 2025, at The Hard Rock Hotel NYC. The company will participate in one-on-one meetings with institutional investors and senior Maxim analysts during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on October 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL2lS8p0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","BK4112","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","MYNZ","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2573250289","title":"Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2573250289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573250289?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:00","pubTimestamp":1759928436,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has announced positive topline results from a feasibility study evaluating a non-invasive blood-based screening test for the early detection of pancreatic cancer. The study assessed 18 proprietary mRNA biomarkers and identified a panel that demonstrated 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls within a 30-subject cohort. The results confirmed the clinical accuracy and utility of the biomarkers, and the company plans to initiate a larger clinical study using banked retrospective samples to further evaluate biomarker performance across different stages of pancreatic cancer. This future study will utilize next-generation sequencing technologies and is part of Mainz Biomed's broader strategy to develop accessible molecular diagnostics for early cancer detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL1S70Qx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","MYNZ","BK4112","IE00BKPKM429.USD","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2572063611","title":"Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2572063611","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572063611?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:26","pubTimestamp":1759526786,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL5WWplZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2571634291","title":"Mainz Biomed NV to Showcase Future of Colorectal Cancer Screening at World Endoscopy Organization Committee Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2571634291","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571634291?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:01","pubTimestamp":1759233690,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a diagnostics company specializing in early cancer detection, will participate in the upcoming plenary session of the World Endoscopy Organization  Committee for Colorectal Cancer Screening on October 3, 2025, in Berlin. At the event, Dr. Lena Krammes, Senior Scientist at Mainz Biomed, will present the company's latest findings on RNA-based diagnostics for the detection and prevention of precancerous lesions, comparing early evidence from their RNA-based screening test to various FIT  cut-offs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL5b8cWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://mainzbiomed.com","stockEarnings":[{"period":"1week","weight":0.296},{"period":"1month","weight":-0.3557},{"period":"3month","weight":-0.3391},{"period":"6month","weight":-0.5381},{"period":"1year","weight":-0.8534},{"period":"ytd","weight":-0.3154}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.1502},{"month":2,"riseRate":0.2,"avgChangeRate":-0.122057},{"month":3,"riseRate":0.6,"avgChangeRate":-0.06002},{"month":4,"riseRate":0.25,"avgChangeRate":-0.148679},{"month":5,"riseRate":0.25,"avgChangeRate":-0.028304},{"month":6,"riseRate":0,"avgChangeRate":-0.291752},{"month":7,"riseRate":0.75,"avgChangeRate":0.072818},{"month":8,"riseRate":0,"avgChangeRate":-0.153442},{"month":9,"riseRate":0,"avgChangeRate":-0.167388},{"month":10,"riseRate":0.25,"avgChangeRate":-0.076172},{"month":11,"riseRate":0.25,"avgChangeRate":-0.142413},{"month":12,"riseRate":0.6,"avgChangeRate":-0.115676}],"exchange":"NASDAQ","name":"Mainz Biomed B.V.","nameEN":"Mainz Biomed B.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mainz Biomed B.V.(MYNZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mainz Biomed B.V.,MYNZ,Mainz Biomed B.V.股票,Mainz Biomed B.V.股票老虎,Mainz Biomed B.V.股票老虎国际,Mainz Biomed B.V.行情,Mainz Biomed B.V.股票行情,Mainz Biomed B.V.股价,Mainz Biomed B.V.股市,Mainz Biomed B.V.股票价格,Mainz Biomed B.V.股票交易,Mainz Biomed B.V.股票购买,Mainz Biomed B.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mainz Biomed B.V.(MYNZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction